Literature DB >> 12519392

Definition of the HLA-A2 restricted peptides recognized by human CD8+ effector T cells by flow-assisted sorting of the CD8+ CD45RA+ CD28- T cell subpopulation.

H Höhn1, M Jülch, H Pilch, C Kortsik, G Tully, C Neukirch, K Freitag, M Maeurer.   

Abstract

In response to antigenic stimulation, naive MHC-class I restricted and antigen-specific CD8+ CD45RA+ CD28+ T cells undergo clonal expansion, differentiate into CD8+ CD45RO+ memory T cells and convert to CD8+ CD45RA+ CD28- T cells displaying potent immune effector functions upon re-encounter with the nominal antigen. We show that the effector CD8+ CD45RA+ CD28- T cell subset is expanded in peripheral blood lymphocytes (PBL) from patients with human papilloma virus (HPV)+ cervical lesions as well as in PBL from patients with pulmonary tuberculosis. Flow-cytometric cell sorted CD8+ CD45RA+ CD28- and CD8+ CD45RA+ CD28- T cells were tested for recognition of HLA-A2 restricted peptides derived either from the human papillomavirus (HPV)16-E7 gene product, or from M. tuberculosis antigens. Mostly CD8+ CD45+ CD28- T cells define antigen/peptide-specific and MHC-restricted responses. These data were confirmed in PBL from patients with tuberculosis using HLA-A2 tetramer-complexes loaded with a peptide from the M. tuberculosis Ag85b antigen by flow cytometry. The sorting of this T cell subset enables to determine the fine specificity of CD8+ effector T cells without the need for in vitro manipulation.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12519392      PMCID: PMC1808613          DOI: 10.1046/j.1365-2249.2003.02036.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  30 in total

1.  Two subsets of memory T lymphocytes with distinct homing potentials and effector functions.

Authors:  F Sallusto; D Lenig; R Förster; M Lipp; A Lanzavecchia
Journal:  Nature       Date:  1999-10-14       Impact factor: 49.962

2.  Skewed maturation of memory HIV-specific CD8 T lymphocytes.

Authors:  P Champagne; G S Ogg; A S King; C Knabenhans; K Ellefsen; M Nobile; V Appay; G P Rizzardi; S Fleury; M Lipp; R Förster; S Rowland-Jones; R P Sékaly; A J McMichael; G Pantaleo
Journal:  Nature       Date:  2001-03-01       Impact factor: 49.962

Review 3.  New methods for assessing T-cell responses.

Authors:  N Bercovici; M T Duffour; S Agrawal; M Salcedo; J P Abastado
Journal:  Clin Diagn Lab Immunol       Date:  2000-11

4.  Expression of CD56 by human papillomavirus E7-specific CD8+ cytotoxic T lymphocytes correlates with increased intracellular perforin expression and enhanced cytotoxicity against HLA-A2-matched cervical tumor cells.

Authors:  A D Santin; P L Hermonat; A Ravaggi; S Bellone; J J Roman; S Jayaprabhu; S Pecorelli; G P Parham; M J Cannon
Journal:  Clin Cancer Res       Date:  2001-03       Impact factor: 12.531

5.  Expansion and functional maturation of human tumor antigen-specific CD8+ T cells after vaccination with antigenic peptide.

Authors:  M J Pittet; D E Speiser; D Liénard; D Valmori; P Guillaume; V Dutoit; D Rimoldi; F Lejeune; J C Cerottini; P Romero
Journal:  Clin Cancer Res       Date:  2001-03       Impact factor: 12.531

6.  CD8 T cells specific for human immunodeficiency virus, Epstein-Barr virus, and cytomegalovirus lack molecules for homing to lymphoid sites of infection.

Authors:  G Chen; P Shankar; C Lange; H Valdez; P R Skolnik; L Wu; N Manjunath; J Lieberman
Journal:  Blood       Date:  2001-07-01       Impact factor: 22.113

7.  Changes in the composition of circulating CD8+ T cell subsets during acute epstein-barr and human immunodeficiency virus infections in humans.

Authors:  M T Roos; R A van Lier; D Hamann; G J Knol; I Verhoofstad; D van Baarle; F Miedema; P T Schellekens
Journal:  J Infect Dis       Date:  2000-07-24       Impact factor: 5.226

8.  Interleukin-7 mediates the homeostasis of naïve and memory CD8 T cells in vivo.

Authors:  K S Schluns; W C Kieper; S C Jameson; L Lefrançois
Journal:  Nat Immunol       Date:  2000-11       Impact factor: 25.606

9.  Identification of major epitopes of Mycobacterium tuberculosis AG85B that are recognized by HLA-A*0201-restricted CD8+ T cells in HLA-transgenic mice and humans.

Authors:  A Geluk; K E van Meijgaarden; K L Franken; J W Drijfhout; S D'Souza; A Necker; K Huygen; T H Ottenhoff
Journal:  J Immunol       Date:  2000-12-01       Impact factor: 5.422

10.  Human CD8+ CTL specific for the mycobacterial major secreted antigen 85A.

Authors:  S M Smith; R Brookes; M R Klein; A S Malin; P T Lukey; A S King; G S Ogg; A V Hill; H M Dockrell
Journal:  J Immunol       Date:  2000-12-15       Impact factor: 5.422

View more
  4 in total

1.  Human leukocyte antigens A*3001 and A*3002 show distinct peptide-binding patterns of the Mycobacterium tuberculosis protein TB10.4: consequences for immune recognition.

Authors:  Rebecca Axelsson-Robertson; Raija K Ahmed; Frank F Weichold; Marthie M Ehlers; Marleen M Kock; Donata Sizemore; Jerry Sadoff; Markus Maeurer
Journal:  Clin Vaccine Immunol       Date:  2010-11-17

2.  Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against Mycobacterium tuberculosis in humans.

Authors:  Heiko Bruns; Christoph Meinken; Philipp Schauenberg; Georg Härter; Peter Kern; Robert L Modlin; Christian Antoni; Steffen Stenger
Journal:  J Clin Invest       Date:  2009-04-20       Impact factor: 14.808

3.  Cellular immune response to pulmonary infections in HIV-infected individuals hospitalized with diverse grades of immunosuppression.

Authors:  M J Miguez-Burbano; D Ashkin; A Rodriguez; R Duncan; M Flores; B Acosta; N Quintero; A Pitchenik
Journal:  Epidemiol Infect       Date:  2006-04       Impact factor: 2.451

4.  A broad profile of co-dominant epitopes shapes the peripheral Mycobacterium tuberculosis specific CD8+ T-cell immune response in South African patients with active tuberculosis.

Authors:  Rebecca Axelsson-Robertson; André G Loxton; Gerhard Walzl; Marthie M Ehlers; Marleen M Kock; Alimuddin Zumla; Markus Maeurer
Journal:  PLoS One       Date:  2013-03-26       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.